SCHEMBL10247979

SCHEMBL10247979

CC(=O)CC(c1ccccc1)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.53
PLA2G1B P04054 1/20 0.49
ATG4B Q9Y4P1 1/20 0.49
KCNA3 P22001 1/20 0.48
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
GPR139 Q6DWJ6 1/20 0.42
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
KCNA5 P22460 1/20 0.42
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
ALB P02768 1/20 0.41
CYP2C9 P11712 1/20 0.41
PCSK7 Q16549 1/20 0.41
HSD17B10 Q99714 1/20 0.41
VKORC1 Q9BQB6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26724801 1.00 TAAR1 (0.53) TAAR1PLA2G1BATG4BKCNA3ALDH1A1
SCHEMBL25152144 0.86 TAAR1 (0.55) TAAR1PLA2G1BATG4BKCNA3MAPT
SCHEMBL17050186 0.86 TAAR1 (0.55) TAAR1PLA2G1BATG4BKCNA3GPR139
SCHEMBL25152385 0.86 TAAR1 (0.55) TAAR1PLA2G1BATG4BKCNA3MAPT
SCHEMBL1234229 0.86 TAAR1 (0.55) TAAR1PLA2G1BATG4BKCNA3MAPT
SCHEMBL185647 0.82 TAAR1 (0.57) TAAR1PLA2G1BATG4BKCNA3ALDH1A1
SCHEMBL9857141 0.82 PDPK1 (0.58) ALDH1A1KDM4EMAPTCES2CES1
SCHEMBL26269490 0.82 TAAR1 (0.52) TAAR1KCNA3ALDH1A1MAPTKMT2A
SCHEMBL11541498 0.81 CYP2D6 (0.57) ALDH1A1KDM4EMAPTKMT2ACES2
SCHEMBL9909376 0.79 KCNA5 (0.64) TAAR1PLA2G1BATG4BKCNA3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111285865-B 9-demethylberberine derivative and preparation method and application thereof 常州方圆制药有限公司 2022-05-17 CN disclosed
CN-111285865-A 9-demethylberberine derivative and preparation method and application thereof 江阴高新科技发展有限公司 2020-06-16 CN disclosed
US-9156840-B2 D2 antagonists, methods of synthesis and methods of use Altos Therapeutics, LLC (US) 2015-10-13 US disclosed
US-20140350005-A1 D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-27 US disclosed
US-8691836-B2 D2 antagonists, methods of synthesis and methods of use Altos Therapeutics, LLC (US) 2014-04-08 US disclosed
US-20120010228-A1 D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE Altos Therapeutics, LLC 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350005-A1 D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE DRD2, DRD3, AVPR2 TAAR1 133/4885PLA2G1B 1534/4885ATG4B 4026/4885
US-20120010228-A1 D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE DRD2, DRD3, AVPR2 TAAR1 133/4885PLA2G1B 1534/4885ATG4B 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.